Cliquer ici pour toutes les publications du CNR-MyRMA en 2020
1368488
T9ZY5DEX
2020
items
1
art-libraries-society-of-north-america-arlisna-reviews
0
default
asc
183
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-6b54a381b25abac06154f9b914a0b926%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22T9ZY5DEX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Phillips%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3E%26%23x201C%3BRifampicin%20and%20Clarithromycin%20%28Extended%20Release%29%20versus%20Rifampicin%20and%20Streptomycin%20for%20Limited%20Buruli%20Ulcer%20Lesions%3A%20A%20Randomised%2C%20Open-Label%2C%20Non-Inferiority%20Phase%203%20Trial%26%23x201D%3B%20by%20Richard%20O%20Phillips%20et%20al.%20%3Ci%3EThe%20Lancet%3C%5C%2Fi%3E.%20395%2C%20no.%2010232%20%28April%2018%2C%202020%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2820%2930047-7%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS0140-6736%2820%2930047-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifampicin%20and%20clarithromycin%20%28extended%20release%29%20versus%20rifampicin%20and%20streptomycin%20for%20limited%20Buruli%20ulcer%20lesions%3A%20a%20randomised%2C%20open-label%2C%20non-inferiority%20phase%203%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20O%22%2C%22lastName%22%3A%22Phillips%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kabiru%20Mohamed%22%2C%22lastName%22%3A%22Abass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fred%20Stephen%22%2C%22lastName%22%3A%22Sarfo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tuah%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Godfred%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Gateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annick%22%2C%22lastName%22%3A%22Chauty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raymond%22%2C%22lastName%22%3A%22Omollo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Ochieng%20Otieno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thaddaeus%20W%22%2C%22lastName%22%3A%22Egondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edwin%20O%22%2C%22lastName%22%3A%22Ampadu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Agossadou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Marion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Line%22%2C%22lastName%22%3A%22Ganlonon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Wansbrough-Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Grosset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M%22%2C%22lastName%22%3A%22Macdonald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Terry%22%2C%22lastName%22%3A%22Treadwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Saunderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Paintsil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Lehman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Frimpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanaa%20Francisca%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raoul%22%2C%22lastName%22%3A%22Saizonou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally-Ann%22%2C%22lastName%22%3A%22Ohene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ymkje%22%2C%22lastName%22%3A%22Stienstra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kingsley%20B%22%2C%22lastName%22%3A%22Asiedu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tjip%20S%22%2C%22lastName%22%3A%22van%20der%20Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Osei%20Mireku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justice%22%2C%22lastName%22%3A%22Abotsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20Ken%22%2C%22lastName%22%3A%22Adu%20Poku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Asamoah-Frimpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bright%22%2C%22lastName%22%3A%22Osei-Wusu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Sarpong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatrice%22%2C%22lastName%22%3A%22Konadu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%22%2C%22lastName%22%3A%22Opoku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Forson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathias%22%2C%22lastName%22%3A%22Ndogyele%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Ofori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felicity%22%2C%22lastName%22%3A%22Aboagye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Berko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%22%2C%22lastName%22%3A%22Amofa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastasia%22%2C%22lastName%22%3A%22Nsiah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joyce%22%2C%22lastName%22%3A%22Mensah-Bonsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ofori%20Nyarko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaw%20Ampem%22%2C%22lastName%22%3A%22Amoako%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elliot%22%2C%22lastName%22%3A%22Koranteng%20Tannor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justice%22%2C%22lastName%22%3A%22Boakye-Appiah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aloysius%22%2C%22lastName%22%3A%22Dzibordzi%20Loglo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mabel%22%2C%22lastName%22%3A%22Sarpong-Duah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernadette%22%2C%22lastName%22%3A%22Agbavor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ardent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Yamadjako%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naomi%22%2C%22lastName%22%3A%22Adanmado%20Gersande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ambroise%22%2C%22lastName%22%3A%22Adeye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martial%22%2C%22lastName%22%3A%22Kindjinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Akpolan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Kiki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Espoir%22%2C%22lastName%22%3A%22Sodjinou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Guegnard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandor-Adrian%22%2C%22lastName%22%3A%22Klis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kristien%22%2C%22lastName%22%3A%22Velding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Till%22%2C%22lastName%22%3A%22Omansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Ofori-Adjei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Eyangoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%22%2C%22lastName%22%3A%22Knell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Faber%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnBuruli%20ulcer%20is%20a%20neglected%20tropical%20disease%20caused%20by%20Mycobacterium%20ulcerans%20infection%20that%20damages%20the%20skin%20and%20subcutis.%20It%20is%20most%20prevalent%20in%20western%20and%20central%20Africa%20and%20Australia.%20Standard%20antimicrobial%20treatment%20with%20oral%20rifampicin%2010%20mg%5C%2Fkg%20plus%20intramuscular%20streptomycin%2015%20mg%5C%2Fkg%20once%20daily%20for%208%20weeks%20%28RS8%29%20is%20highly%20effective%2C%20but%20streptomycin%20injections%20are%20painful%20and%20potentially%20harmful.%20We%20aimed%20to%20compare%20the%20efficacy%20and%20tolerability%20of%20fully%20oral%20rifampicin%2010%20mg%5C%2Fkg%20plus%20clarithromycin%2015%20mg%5C%2Fkg%20extended%20release%20once%20daily%20for%208%20weeks%20%28RC8%29%20with%20that%20of%20RS8%20for%20treatment%20of%20early%20Buruli%20ulcer%20lesions.%5CnMethods%5CnWe%20did%20an%20open-label%2C%20non-inferiority%2C%20randomised%20%281%3A1%20with%20blocks%20of%20six%29%2C%20multicentre%2C%20phase%203%20clinical%20trial%20comparing%20fully%20oral%20RC8%20with%20RS8%20in%20patients%20with%20early%2C%20limited%20Buruli%20ulcer%20lesions.%20There%20were%20four%20trial%20sites%20in%20hospitals%20in%20Ghana%20%28Agogo%2C%20Tepa%2C%20Nkawie%2C%20Dunkwa%29%20and%20one%20in%20Benin%20%28Pob%5Cu00e8%29.%20Participants%20were%20included%20if%20they%20were%20aged%205%20years%20or%20older%20and%20had%20typical%20Buruli%20ulcer%20with%20no%20more%20than%20one%20lesion%20%28caterories%20I%20and%20II%29%20no%20larger%20than%2010%20cm%20in%20diameter.%20The%20trial%20was%20open%20label%2C%20and%20neither%20the%20investigators%20who%20took%20measurements%20of%20the%20lesions%20nor%20the%20attending%20doctors%20were%20masked%20to%20treatment%20assignment.%20The%20primary%20clinical%20endpoint%20was%20lesion%20healing%20%28ie%2C%20full%20epithelialisation%20or%20stable%20scar%29%20without%20recurrence%20at%2052%20weeks%20after%20start%20of%20antimicrobial%20therapy.%20The%20primary%20endpoint%20and%20safety%20were%20assessed%20in%20the%20intention-to-treat%20population.%20A%20sample%20size%20of%20332%20participants%20was%20calculated%20to%20detect%20inferiority%20of%20RC8%20by%20a%20margin%20of%2012%25.%20This%20study%20was%20registered%20with%20ClinicalTrials.gov%2C%20NCT01659437.%5CnFindings%5CnBetween%20Jan%201%2C%202013%2C%20and%20Dec%2031%2C%202017%2C%20participants%20were%20recruited%20to%20the%20trial.%20We%20stopped%20recruitment%20after%20310%20participants.%20Median%20age%20of%20participants%20was%2014%20years%20%28IQR%2010%5Cu201329%29%20and%20153%20%2852%25%29%20were%20female.%20297%20patients%20had%20PCR-confirmed%20Buruli%20ulcer%3B%20151%20%2851%25%29%20were%20assigned%20to%20RS8%20treatment%2C%20and%20146%20%2849%25%29%20received%20oral%20RC8%20treatment.%20In%20the%20RS8%20group%2C%20lesions%20healed%20in%20144%20%2895%25%2C%2095%25%20CI%2091%20to%2098%29%20of%20151%20patients%2C%20whereas%20lesions%20healed%20in%20140%20%2896%25%2C%2091%20to%2099%29%20of%20146%20patients%20in%20the%20RC8%20group.%20The%20difference%20in%20proportion%2C%20%5Cu22120%5Cu00b75%25%20%28%5Cu20135%5Cu00b72%20to%204%5Cu00b72%29%2C%20was%20not%20significantly%20greater%20than%20zero%20%28p%3D0%5Cu00b759%29%2C%20showing%20that%20RC8%20treatment%20is%20non-inferior%20to%20RS8%20treatment%20for%20lesion%20healing%20at%2052%20weeks.%20Treatment-related%20adverse%20events%20were%20recorded%20in%2020%20%2813%25%29%20patients%20receiving%20RS8%20and%20in%20nine%20%287%25%29%20patients%20receiving%20RC8.%20Most%20adverse%20events%20were%20grade%201%5Cu20132%2C%20but%20one%20%281%25%29%20patient%20receiving%20RS8%20developed%20serious%20ototoxicity%20and%20ended%20treatment%20after%206%20weeks.%20No%20patients%20needed%20surgical%20resection.%20Four%20patients%20%28two%20in%20each%20study%20group%29%20had%20skin%20grafts.%5CnInterpretation%5CnFully%20oral%20RC8%20regimen%20was%20non-inferior%20to%20RS8%20for%20treatment%20of%20early%2C%20limited%20Buruli%20ulcer%20and%20was%20associated%20with%20fewer%20adverse%20events.%20Therefore%2C%20we%20propose%20that%20fully%20oral%20RC8%20should%20be%20the%20preferred%20therapy%20for%20early%2C%20limited%20lesions%20of%20Buruli%20ulcer.%5CnFunding%5CnWHO%20with%20additional%20support%20from%20MAP%20International%2C%20American%20Leprosy%20Missions%2C%20Fondation%20Raoul%20Follereau%20France%2C%20Buruli%20ulcer%20Groningen%20Foundation%2C%20Sanofi-Pasteur%2C%20and%20BuruliVac.%22%2C%22date%22%3A%222020-04-18%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS0140-6736%2820%2930047-7%22%2C%22ISSN%22%3A%220140-6736%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0140673620300477%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T09%3A58%3A39Z%22%7D%7D%5D%7D
“Rifampicin and Clarithromycin (Extended Release) versus Rifampicin and Streptomycin for Limited Buruli Ulcer Lesions: A Randomised, Open-Label, Non-Inferiority Phase 3 Trial” by Richard O Phillips et al. The Lancet. 395, no. 10232 (April 18, 2020). https://doi.org/10.1016/S0140-6736(20)30047-7.